Research we are currently funding:
This project aims to discover how a particular protein called BRD4 leads to the development and growth of tumours in children with TERT-rearranged neuroblastoma.
This study will compare current standard PCV treatment to oral temozolomide chemotherapy combined with with radiation, for effectiveness with fewer side effects.
A synthetic retinoid (a compound derived from vitamin A) has been found to acts powerfully against Diffuse intrinsic pontine gliomas (DIPG) cells.
A/Prof Claire Wakefield is testing interventions that provide support and improve long term outcomes to childhood cancer survivors and their families.
The aim of this 5 year program is to increase survival rates of children with Acute Lymphoblastic Leukaemia (ALL) and ultimately develop prevention strategies.
Neuroblastoma accounts for around 15% of deaths from cancer in children. Dr MacKenzie and her team have found that blocking a certain protein can kill neuroblastoma cells.
Impact we've achieved with our research:
One of Murray’s proudest achievements so far has been the development of unique technology that helps prevent relapse in children with acute lymphoblastic leukaemia.
Professor Murray Norris and his team developed a pioneering tool that is improving the survival of children with leukaemia by stopping the cancer from returning.